首页>投融资
Orbital Therapeutics
A轮
Orbital Therapeutics is focused on developing RNA therapeutics, including vaccines, immunomodulators, protein replacement and regenerative medicine, for multiple diseases.In April 2023, Orbital Therapeutics successfully closed of 270 million Series A financing.By September 2022, the company had received initial funding by ARCH Venture Partners with Participation from a16z Bio + Health and Newpath Partners
基本信息
-
公司全称Orbital Therapeutics
-
类型RNA药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址Cambridge Massachusetts; US;
-
联系电话
-
邮箱careers@orbitaltx.com
-
成立时间2022-01-01
投融资
-
2023-04-26A轮2.7亿美元Alexandria Venture InvestmentsRellim Capital ManagementHeritage Medical SystemsEXORARCH Venture PartnersMoore Strategic VenturesRedmile GroupiGlobe Platinum Funda16z Bio+HealthAbu Dhabi Growth FundCasdin CapitalAgent CapitalInvusNewpath Partners
-
2023-04-26A轮2.7亿美元Redmile Groupa16z Bio+HealthAgent CapitalAbu Dhabi Growth FundRellim Capital ManagementARCH Venture PartnersNewpath Partners
-
2022-09-07未公开未透露Newpath Partnersa16z Bio+HealthARCH Venture Partners
-
2022-09-07未透露未透露ARCH Venture Partnersa16z Bio+HealthNewpath Partners
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息